according to the OSHA Hazard Communication Standard



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/26/2023 3.10 09/30/2023 1731674-00014 Date of first issue: 06/05/2017

SECTION 1. IDENTIFICATION

Product name : Moxifloxacin Solid Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Acute toxicity (Oral) : Category 4

Eye irritation : Category 2B

Reproductive toxicity : Category 2

Specific target organ toxicity

- repeated exposure

Category 2 (Liver)

GHS label elements

Hazard pictograms





Signal Word : Warning

Hazard Statements : H302 Harmful if swallowed.

H320 Causes eye irritation.

H361d Suspected of damaging the unborn child.

H373 May cause damage to organs (Liver) through prolonged or

repeated exposure.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust, fume, gas, mist, vapors or spray.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

according to the OSHA Hazard Communication Standard



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/26/2023 3.10 09/30/2023 1731674-00014 Date of first issue: 06/05/2017

P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel

unwell. Rinse mouth.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy

to do. Continue rinsing.

P308 + P313 IF exposed or concerned: Get medical attention. P337 + P313 If eye irritation persists: Get medical attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	>= 40 - <= 70
Cellulose	9004-34-6	>= 10 - <= 30

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

according to the OSHA Hazard Communication Standard



Moxifloxacin Solid Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04/26/2023 09/30/2023 1731674-00014 Date of first issue: 06/05/2017 3.10

Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and Harmful if swallowed. Causes eye irritation.

delayed

Suspected of damaging the unborn child.

May cause damage to organs through prolonged or repeated

exposure.

First Aid responders should pay attention to self-protection, Protection of first-aiders

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

Water spray Suitable extinguishing media :

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

None known.

media

Specific hazards during fire

Exposure to combustion products may be a hazard to health.

fiahtina

Hazardous combustion prod-

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Avoid release to the environment. **Environmental precautions**

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to the OSHA Hazard Communication Standard



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/26/2023 3.10 09/30/2023 1731674-00014 Date of first issue: 06/05/2017

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust, fume, gas, mist, vapors or spray.

Do not swallow. Do not get in eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Moxifloxacin HCL	186826-86-8	TWA	1000 μg/m3 (OEB 1)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m³	OSHA Z-1

Engineering measures : Use feasible engineering controls to minimize exposure to

compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where

concentrations are above recommended limits or are

unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and

according to the OSHA Hazard Communication Standard



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/26/2023 3.10 09/30/2023 1731674-00014 Date of first issue: 06/05/2017

use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Hygiene measures

Work uniform or laboratory coat.

: If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : solid

Color : pink

Odor : odorless

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : No data available

Upper explosion limit / Upper : No data available

according to the OSHA Hazard Communication Standard



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/26/2023 3.10 09/30/2023 1731674-00014 Date of first issue: 06/05/2017

flammability limit

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : Not applicable

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Skin contact Ingestion Eye contact

according to the OSHA Hazard Communication Standard



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/26/2023 3.10 09/30/2023 1731674-00014 Date of first issue: 06/05/2017

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,886 mg/kg

Method: Calculation method

Components:

Moxifloxacin HCL:

Acute oral toxicity : LD50 (Rat): 1,320 mg/kg

LD50 (Mouse): > 435 mg/kg

LD50 (Monkey): 1,500 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Moxifloxacin HCL:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Causes eye irritation.

Components:

Moxifloxacin HCL:

Species : Rabbit

Result : Moderate eye irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

according to the OSHA Hazard Communication Standard



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/26/2023 3.10 09/30/2023 1731674-00014 Date of first issue: 06/05/2017

Germ cell mutagenicity

Not classified based on available information.

Components:

Moxifloxacin HCL:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: positive

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: in vitro micronucleus test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Application Route: Oral

Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

according to the OSHA Hazard Communication Standard



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/26/2023 3.10 09/30/2023 1731674-00014 Date of first issue: 06/05/2017

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Moxifloxacin HCL:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: LOAEL: 500 mg/kg body weight

Result: Effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Monkey Application Route: Oral

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: negative

Test Type: Embryo-fetal development

Species: Rabbit

Application Route: Intravenous injection

Developmental Toxicity: LOAEL: 20 mg/kg body weight

Symptoms: Skeletal malformations.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Liver) through prolonged or repeated exposure.

Components:

Moxifloxacin HCL:

Target Organs : Liver

Assessment : May cause damage to organs through prolonged or repeated

exposure.

according to the OSHA Hazard Communication Standard



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/26/2023 3.10 09/30/2023 1731674-00014 Date of first issue: 06/05/2017

Repeated dose toxicity

Components:

Moxifloxacin HCL:

Species : Rat LOAEL : 100 mg/kg

Application Route : Oral Exposure time : 4 Weeks

Species : Rat

NOAEL: 100 mg/kgApplication Route: OralExposure time: 13 WeeksTarget Organs: Liver

Symptoms : Liver disorders

Species : Rat

NOAEL : 20 mg/kg

Application Route : Oral

Exposure time : 6 Months

Target Organs : Liver

Symptoms : Liver disorders

Species : Monkey
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

Symptoms : No adverse effects.

Species : Monkey
NOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 13 Weeks

Target Organs : Gastrointestinal tract

Symptoms : Vomiting

Species : Monkey
Application Route : Oral
Exposure time : 26 Weeks
Target Organs : Liver

Symptoms : Liver disorders

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Aspiration toxicity

Not classified based on available information.

according to the OSHA Hazard Communication Standard



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/26/2023 3.10 09/30/2023 1731674-00014 Date of first issue: 06/05/2017

Experience with human exposure

Components:

Moxifloxacin HCL:

Ingestion : Symptoms: Nausea, Abdominal pain, Headache, Dizziness,

central nervous system effects, joint pain

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

according to the OSHA Hazard Communication Standard



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/26/2023 3.10 09/30/2023 1731674-00014 Date of first issue: 06/05/2017

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Acute toxicity (any route of exposure)

Reproductive toxicity

Specific target organ toxicity (single or repeated exposure)

Serious eye damage or eye irritation

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Moxifloxacin HCL 186826-86-8 Cellulose 9004-34-6

California Permissible Exposure Limits for Chemical Contaminants

Cellulose 9004-34-6

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

according to the OSHA Hazard Communication Standard




Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/26/2023 3.10 09/30/2023 1731674-00014 Date of first issue: 06/05/2017

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



Special hazard

HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL : USA. NIOSH Recommended Exposure Limits

OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim-

its for Air Contaminants

ACGIH / TWA : 8-hour, time-weighted average

NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour

workday during a 40-hour workweek

OSHA Z-1 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization: ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse)

according to the OSHA Hazard Communication Standard



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 04/26/2023 3.10 09/30/2023 1731674-00014 Date of first issue: 06/05/2017

Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8